Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure
Authors:
Open Access
- 15 April 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (10) , 1910-1918
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of end-stage renal failure (ESRF). The epidemiology of the incident ADPKD patient cohort requiring renal replacement therapy (RRT) in England and Wales has not been described. We used a retrospective cohort design. Incident adult patients commencing RRT between 1 January 2000 and 31 December 2011 in England and Wales were identified from the UK Renal Registry. Patients were stratified into three groups based on primary renal diagnosis (PRD): (i) ADPKD, (ii) diabetes as PRD, (iii) individuals with another PRD (‘other’). Baseline demographics, comorbidity, care-related measures and outcomes including patient survival are described. A total of 52 608 individuals started RRT during the study period, 3598 (6.8%) had ADPKD, 12 137 (23.1%) diabetes as PRD and 36 873 had another PRD diagnosis. The median age of commencing RRT was 55 years in the ADPKD group compared with 62 and 66 years in those with diabetes or ‘other’ PRD, respectively. The median age of starting RRT did not change within the ADPKD group over the 10-year period. Median age at death was similar across all groups. The ADPKD group had a lower hazard for all-cause mortality compared with the ‘other’ PRD group (adjusted hazard ratio 0.45, 95% CI 0.38–0.53). In all PRD groups, crude mortality rates had improved between 2000–06 and 2007–11. Although engaged in renal services earlier than some other patient groups, individuals with ADPKD start RRT at a younger age and this has remained unchanged over the last decade. Developing a nationwide cohort and an enhanced disease-specific dataset would facilitate a wide range of research and quality improvement initiatives to try to modify progression to ESRF and the course of RRT.Keywords
This publication has 28 references indexed in Scilit:
- Type of PKD1 Mutation Influences Renal Outcome in ADPKDJournal of the American Society of Nephrology, 2013
- The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centreQJM: An International Journal of Medicine, 2013
- Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric StudyPLOS ONE, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- The ERA-EDTA Working Group on inherited kidney disordersNephrology Dialysis Transplantation, 2012
- The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney diseaseNephrology Dialysis Transplantation, 2011
- Autosomal dominant polycystic kidney disease: the last 3 yearsKidney International, 2009
- Volume Progression in Polycystic Kidney DiseaseNew England Journal of Medicine, 2006
- The Position of the Polycystic Kidney Disease 1 (PKD1) Gene Mutation Correlates with the Severity of Renal DiseaseJournal of the American Society of Nephrology, 2002